In the last decade, the treatment pattern based on immune checkpoint inhibitor (ICI) targeting programmed cell death ligand 1 (PD-1) and programmed cell death ligand 1 (PD-L1), has achieved significant clinical efficacy in advanced and locally advanced NSCLC patients with driver gene negative and become the standard treatment for such population [7]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.